logo-loader

Antibe Therapeutics is looking to the future after successful past year

Last updated: 12:26 04 Jul 2019 EDT, First published: 13:40 04 Jul 2019 EDT

Antibe Therapeutics  (CVE:ATE-OTCQB:ATBPF) CEO Dan Legault joined Steve Darling from the Proactive Investors Toronto studio to discuss his recent letter to the shareholders in which he outlined the company’s last year.

Legault also talked about the year ahead and the prep work they are doing for a major meeting with the U.S. Food and Drug Administration.

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the next...

on 12/8/20